14
Disclaimer
is pocket guide is derived om recommendations in the American Society of Clinical
Oncology Guideline. is resource is a practice tool based on ASCO
®
practice guidelines and is
not intended to substitute for the independent professional judgment of the treating physician.
Practice guidelines do not account for individual variation among patients. is pocket guide
does not purport to suggest any particular course of medical treatment. Use of the practice
guidelines and this resource are voluntary. e practice guidelines and additional information
are available at www.asco.org/supportive-care-guidelines. Copyright ©2019 by American
Society of Clinical Oncology. All rights reserved.
Source
Noam Yarom, Charles L. Shapiro, Douglas E. Peterson, Catherine H. Van Poznak, Kari
Bohlke, Salvatore L. Ruggiero, Cesar A. Migliorati, Aliya Khan, Archie Morrison, Holly
Anderson, Barbara A. Murphy, Devena Alston-Johnson, Rui Amaral Mendes, Beth Michelle
Beadle, Siri Beier Jensen, Deborah P. Saunders. Medication-Related Osteonecrosis of the Jaw:
MASCC/ISOO/ASCO Clinical Practice Guideline. J Clin Oncol. 2019 July 22
DOI: 10.1200/JCO.19.01186
106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2019 All rights reserved
ASCOONJ1982a
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, and other clinical
tools and resources, is available at www.asco.org/supportive-care-guidelines.
Abbreviations
BMA, bone-modifying agent; ISOO, International Society of Oral Oncolog y;
IV, intravenous; MASCC, Multinational Association of Supportive Care in Cancer;
MRONJ, medication-related osteonecrosis of the jaw; ONJ, osteonecrosis of the jaw;
SC, subcutaneous; VAS, visual analog scale
Recommendation Grading
Type Evidence Quality
Strength of
Recommendation
EB Evidence-based H High Strong
FC
Formal consensus I Intermediate Moderate
IC Informal consensus L Low Weak
Ins Insufficient
